- Report
- October 2024
- 186 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- October 2024
- 192 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- February 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €3503EUR$3,750USD£2,964GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3503EUR$3,750USD£2,964GBP
- Report
- November 2021
- 101 Pages
Global
From €4204EUR$4,500USD£3,556GBP
- Report
- August 2022
- 120 Pages
Global
From €4438EUR$4,750USD£3,754GBP
- Report
- April 2023
- 117 Pages
Global
From €4438EUR$4,750USD£3,754GBP
- Report
- March 2024
- 200 Pages
Global
From €3877EUR$4,150USD£3,280GBP
- Report
- January 2024
- 156 Pages
United States
€3550EUR$3,800USD£3,003GBP
- Report
- January 2024
- 114 Pages
United States
€3270EUR$3,500USD£2,766GBP
- Report
- July 2018
- 30 Pages
Global
From €9342EUR$10,000USD£7,903GBP

Symbicort is a combination medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It contains two active ingredients: budesonide, a corticosteroid, and formoterol, a long-acting beta-agonist. Symbicort is used to reduce inflammation and open up the airways in the lungs, allowing for easier breathing. It is available in both an inhaler and a dry powder inhaler.
Symbicort is part of a larger class of respiratory drugs known as bronchodilators. These drugs are used to treat a variety of respiratory conditions, including asthma, COPD, and bronchitis. Other bronchodilators include albuterol, salmeterol, and ipratropium.
Symbicort is manufactured by AstraZeneca, a British-Swedish pharmaceutical company. Other companies that produce similar medications include GlaxoSmithKline, Boehringer Ingelheim, and Merck. Show Less Read more